Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma

Blood

Volumn 102, Issue 5, 2003, Pages 1833-1841

  Gaidano, Gianluca ^b   Pasqualucci, Laura ^b   Capello, Daniela ^b   Berra, Eva ^b   Deambrogi, Clara ^b   Rossi, Davide ^b   Larocca, Luigi Maria ^b   Gloghini, Annunziata ^b   Carbone, Antonino ^b   Dalla Favera, Riccardo ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; IMMUNOGLOBULIN HEAVY CHAIN; VIRUS ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMINO ACID SUBSTITUTION; ARTICLE; B CELL LYMPHOMA; BCL 6 GENE; BRAIN LYMPHOMA; BURKITT LYMPHOMA; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL ARTICLE; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; EXON; GENE MUTATION; GENE REARRANGEMENT; HISTOGENESIS; HUMAN; HUMAN CELL; IMMUNOGLOBULIN VARIABLE REGION; INTRON; LYMPHOMA; NONHODGKIN LYMPHOMA; NUCLEOTIDE SEQUENCE; ONCOGENE C MYC; PATHOGENESIS; PAX 5 GENE; PIM 1 GENE; PRIORITY JOURNAL; PROTO ONCOGENE; RHOH GENE; SOMATIC MUTATION; TRANSACTIVATION; TTF GENE; TUMOR SUPPRESSOR GENE; VIRUS INFECTION;

EID: 0042441971     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-11-3606     Document Type: Article

References (46)

1. Tirelli U, Spina M, Gaidano G, Vaccher E, Franceschl S, Carbone A. Epidemiological, biological and clinical features of HIV-related lymphomas in the era of highly active antiretroviral therapy. AIDS. 2000;14:1675-1688.
2. Gaidano G, Capello D, Carbone A. The molecular basis of AIDS-related lymphomagenesis. Semin Oncol. 2000;27:431-441.
3. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Haematopoletic and Lymphold Tissues. Lyon, France: IARC Press; 2001.
4. Carbone A, Gloghini A, Larocca LM, et al. Expression profile of MUM1/IRF-4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. Blood. 2001;97:744-751.
5. Küppers R, Klein U, Hansmann ML, Rajewsky K. Cellular origin of human B-cell lymphomas. N Engl J Med. 1999;341:1520-1529.
6. Stevenson FK, Sahota SS, Ottensmeier CH, Zhu D, Forconi F, Hamblin TJ. The occurrence and significance of V gene mutations in B cell-derived human malignancy. Adv Cancer Res. 2001;83:81-116.
7. Shen HM, Peters A, Baron B, Zhu X, Storb U. Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes. Science, 1998;280:1750-1752.
8. Pasqualucci L, Migliazza A, Fracchiolla N, et al. BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. Proc Natl Acad Sci U S A. 1988;95:11816-11821.
9. Peng H-Z, Du M-Q, Koulis A, et al. Nonimmunoglobulin gene hypermutation in germinal center B cells. Blood. 1999;93:2167-2172.
10. Müschen M, Re D, Jungnickel B, Diehl V, Rajewsky K, Küppers R. Somatic mutation of the CD95 gene in human B cells as a side-effect of the germinal center reaction. J Exp Med. 2000;18:1833-1840.
11. Pasqualucci L, Neumeister P, Goossens T, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature. 2001;412:341-346.
12. Storb U. Progress in understanding the mechanism and consequences of somatic hypermutation. Immunol Rev. 1998;162:5-11.
13. Storb U, Peters A, Klotz E, et al. Cis-acting sequences that affect somatic hypermutation of Ig genes. Immunol Rev. 1998;162:153-160.
14. Neuberger MS, Ehrenstein MR, Klix N, et al. Monitoring and interpreting the intrinsic features of somatic hypermutation. Immunol Rev. 1998;162:107-116.
15. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell. 2000;102:553-563.
16. Revy P, Muto T, Levy Y, et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell, 2000;102:565-575
17. Martin A, Scharff MD. AID and mismatch repair in antibody diversification. Nat Rev Immunol. 2002;8:605-614.
18. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392.
19. Cesarman E, Moore PS, Rao PH, Inghirami G, Knowles DM, Chang Y. In vitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi's sarcoma-associated herpesvirus-like (KSHV) DNA sequences. Blood. 1995;86:2708-2714.
20. Gaidano G, Cechova K, Chang Y, Moore PS, Knowles DM, Dalla-Favera R. Establishment of AIDS-related lymphoma cell lines from lymphomatous effusions. Leukemia. 1996;10:1237-1240.
21. Renne R, Zhong W, Herndier B, et al. Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat Med. 1996;2:342-346.
22. Carbone A, Cilia AM, Gloghini A, et al. Establishment and characterization of EBV-positive and EBV-negative primary effusion lymphoma cell lines harbouring human herpesvirus type-8. Br J Haematol. 1998;102:1081-1089.
23. Carbone A, Cilia AM, Gloghini A, et al. Characterization of a novel HHV-8-positive cell line reveals implications for the pathogenesis and cell cycle control of primary effusion lymphoma. Leukemia. 2000;14:1301-1309.
24. Ballerini P, Gaidano G, Gong JZ, et al. Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Blood. 1993;81:166-176.
25. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.
26. Capello D, Vitolo U, Pasqualucci L, et al. Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia. Blood. 2000;95, 651-659.
27. Küppers R, Rajewsky K, Hansmann ML. Diffuse large cell lymphomas are derived from mature B cells carrying V region genes with a high load of somatic mutation and evidence for selection of antibody expression. Eur J Immunol. 1997;27:1398-1405.
28. Fais F, Gaidano G, Capello D, et al. Immunoglobulin V region gene use and structure suggest antigen selection in AIDS-related primary effusion lymphomas. Leukemia. 1999;13:1093-1099.
29. Migliazza A, Martinotti S, Chen W, et al. Frequent somatic hypermutation of the 5′ noncoding region of the BCL-6 gene In B-cell lymphoma. Proc Natl Acad Sci U S A. 1995;92:12520-12524.
30. Klein U, Goossens T, Fischer M, et al. Somatic hypermutation in normal and transformed human B-cells. Immunol Rev. 1998;162:261-280.
31. Rabbits TH, Hamlyn PH, Baer R. Altered nucleotide sequences of a translocated c-myc gene in Burkitt lymphoma. Nature. 1983;306:760-765.
32. Cesarman E, Dalla-Favera R, Bentley D, Groudine M. Mutations in the first exon are associated with altered transcription of c-myc in Burkitt lymphoma. Science. 1987;238:1272-1275.
33. Dang CV. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol. 1999;19:1-11.
34. Sale JE, Neuberger MS. TdT-accessible breaks are scattered over the immunoglobulin V domain in a constitutively hypermutating B cell line. Immunity. 1998;9:859-869.
35. Zan H, Cerutti A, Dramitinos P, Schaffer A, Li Z, Casali P. Induction of Ig somatic hypermutation and class switching in a human monoclonal IgM+ IgD+ B cell line in vitro: definition of the requirements and modalities of hypermutation. J Immunol. 1999;162:3437-3447.
36. Cuypers HT, Selten G, Quint W, et al. Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell. 1984;37:141-150.
37. Hoover D, Friedmann M, Reeves R, Magnuson MS. Recombinant human pim-1 protein exhibits serine/threonine kinase activity. J Biol Chem. 1991;266:14018-14023.
38. Bhatia K, Huppi K, Spangler G, Siwarski D, Iyer R, Magrath I. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nat Genet. 1993;5:56-61.
39. Yano T, Sander CA, Clark HM, Dolezal MV, Jaffe ES, Raffeld M. Clustered mutations in the second exon of the MYC gene in sporadic Burkitt's lymphoma. Oncogene. 1993;8:2741-2748.
40. Bhatia K, Spangler G, Gaidano G, Hamdy N, Dalla-Favera R, Magrath I. Mutations in the coding region of c-myc occur frequently in acquired immunodeficiency syndrome-associated lymphomas. Blood. 1994;84:883-888.
41. Hoang AT, Lutterbach B, Lewis BC, et al. A link between increased transforming activity of lymphoma-derived MYC mutant alleles, their defective regulation by p107, and altered phosphorylation of the c-Myc transactivation domain. Mol Cell Biol. 15:4031-4042.
42. Gregory MA, Hann SR. c-Myc proteolysis by the ubiquitin-protasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells. Mol Cell Biol. 2000;20:2423-2435.
43. Gu W, Bhatia K, Magrath I, Dang CV, Dalla-Favera R. Binding and suppression of the Myc transcriptional activation domain by p107. Science. 1994;264:251-254.
44. Morrison AM, Nutt SL, Thevenin C, Rolink A, Busslinger M. Loss- and gain-of-function mutations reveal an important role of BSAP (Pax-5) at the start and end of B cell differentiation. Semin Immunol. 1998;10:133-142.
45. Preudhomme C, Roumier C, Hildebrand MP, et al. Nonrandom 4p13 rearrangements of the RhoH/TTF gene, encoding a GTP-binding protein, in non-Hodgkin's lymphoma and multiple myeloma. Oncogene. 2000;19:2023-2032.
46. Akasaka H, Akasaka T, Kurata M, et al. Molecular anatomy of BCL6 translocations revealed by long-distance polymerase chain reaction-based assays. Cancer Res. 2000;60:2335-2341.